Tag: pandemic

  • Why the Dow Just Slipped 350 Points

    Why the Dow Just Slipped 350 Points

    After hitting all-time highs on excessive optimism, markets are pulling back. At the moment, the Dow is down about 300 points, as the NASDAQ slips $115 points. All after retail sales came in at a worse than expected decline of 1.1% in July — far worse than expectations for a drop of 0.3%.  All thanks…

  • Why Cruise Stocks Could Sink Even More

    Why Cruise Stocks Could Sink Even More

    Cruise stocks are getting sunk. All thanks to the spread of the coronavirus all around the world. In the U.S. for example, according to CNBC, “Cases have rebounded in the U.S. this month with the delta variant spreading among the unvaccinated. The U.S. is averaging nearly 30,000 new cases a day in the last 7-days…

  • It’s Time to Buy Back into Casino Stocks

    It’s Time to Buy Back into Casino Stocks

    Keep an eye on casino stocks. With pandemic fears fading, casinos are back to raking in the green.  In the first quarter of the year, U.S. commercial gaming revenue topping $11 billion in the first quarter of 2021, according to the American Gaming Association (AGA). “The revenue total marks a 4.1 percent increase over the…

  • Ocugen Could Easily Soar to Higher Highs

    Ocugen Could Easily Soar to Higher Highs

    Ocugen has been explosive. Since December 2020, the stock ran from a low of 29 cents to $13 good for a return of 4,383%.  However, even after the run, OCGN could see further upside. All after its development partner, Bharat Biotech, announced the results of the first interim analysis of its Phase 3 study of…

  • The Top 3 Vaccine Trades that Should be in All Portfolios

    The Top 3 Vaccine Trades that Should be in All Portfolios

    Moderna (MRNA) has been incredibly explosive for us. The first time we highlighted opportunity, the stock traded at $72 on Oct. 20.  At the moment, it’s up to $171.92 in pre-market, and we still believe it could rally to $200. For one, “This positive primary analysis confirms the ability of our vaccine to prevent COVID-19…

  • Weakness in Beyond Meat Could be an Interesting Opportunity

    Weakness in Beyond Meat Could be an Interesting Opportunity

    Keep an eye on Beyond Meat (BYND). Over the last few days, the plant-based stock fell more than $5 a share after COVID-19 took a bit out of earnings.  The company posted a loss of $19.3 million, or 31 cents a share, as compared to net income of $4.1 million, or six cents a share…

  • Top “Blood in the Streets” Opportunities to Consider

    Top “Blood in the Streets” Opportunities to Consider

    Over the last few months, the pandemic crippled the economy, destroying top stocks. However, with a potential vaccine, those stocks may now be great “blood in the streets” opportunities. All on news Pfizer just said its COVID-19 vaccine is 90% effective. “Amazing news from Pfizer with 90% efficacy. This hopefully is the beginning of the…

  • Three Safer Ways to Trade the Pandemic Volatility

    Three Safer Ways to Trade the Pandemic Volatility

    With the virus showing no signs of slowing, here are some of the top opportunities. Each of these should continue pushing higher until we see some relief from COVID-19. Volatility ETFs, such as the ProShares Ultra VIX Short-Term Futures ETF (UVXY) saw further upside as the markets melt down ahead of the U.S. elections, and…

  • One of the Top Ways to Trade the Excessive Volatility

    One of the Top Ways to Trade the Excessive Volatility

    Markets have become incredibly volatile ahead of the elections, and on continued uncertainty over more stimulus.  We’ve seen the market run up hundreds of points, only to close the day down hundreds of points.  It’s been that crazed. This morning, futures are down slightly.  The Dow is down 26, as the NASDAQ remains flat.  The…

  • This Pandemic Stock Has Just Begun to Push Higher

    This Pandemic Stock Has Just Begun to Push Higher

    Keep an eye on Altimmmune Inc. (ALT). The stock is pushing higher thanks to more positive data on its COVID candidate. The company just published positive pre-clinical data for its new single-dose, intranasal COVID-19 vaccine candidate AdCOVID, adding the candidate “stimulates three key immune components: serum neutralizing antibody, T cell responses, and mucosal immunity in the respiratory tract.” “AdCOVID is designed to offer significant…